

## News Release

---

STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

### **Fisher & Paykel Healthcare reminds shareholders of Dividend Reinvestment Plan (DRP), amends formula for calculation of additional shares**

Auckland, New Zealand, 13 June 2023 - Fisher & Paykel Healthcare reminds shareholders of its Dividend Reinvestment Plan, while also advising of amendments to the formula for calculating a DRP participant's entitlement to additional shares.

The DRP was reactivated late last year for eligible shareholders residing in New Zealand, Australia and the United Kingdom. Under this plan, eligible shareholders may elect to reinvest all or part of their cash dividends in additional shares at a 3% discount.

Shareholders not previously enrolled who wish to participate in respect of the FY2023 final dividend will need to opt into the plan via Link Market Services' website at <https://investorcentre.linkgroup.nz/> or return a physical participation form before 5pm on 28 June 2023.

The company also advises of amendments to the plan to ensure that each participating shareholder acquires their shares at the same effective price and does not lose any fractional entitlements to shares as a result of rounding. More specifically, the formula has been amended to:

- a) permit the company to round a participant's entitlement down to the nearest whole share; and
- b) hold the balance of any remaining dividend for the benefit of the participant until the next time the DRP operates.

An updated version of the DRP offer document setting out the terms and conditions of the plan and further details of its operation (including how the number of ordinary shares to be issued to each DRP participant will be calculated) is now available on the company's website at [fphcare.com/drp](https://fphcare.com/drp).

### **About Fisher & Paykel Healthcare**

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company's products are sold in over 120 countries worldwide. For more information about the company, visit our website [www.fphcare.com](https://www.fphcare.com).

### **Media & Investor Contacts:**

Hayden Brown  
Head of Capital Markets and Investor  
Relations  
[hayden.brown@fphcare.co.nz](mailto:hayden.brown@fphcare.co.nz)  
+64 27 807 8073

Dan Adolph  
Senior Communications and Investor Relations  
Manager  
[daniel.adolph@fphcare.co.nz](mailto:daniel.adolph@fphcare.co.nz)  
+64 22 511 4050

Authorised by Raelene Leonard, General Counsel and Company Secretary.